🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer

Recruitingn/aAges 18 Years - anyAllThe Netherlands Cancer Institute
NCT06931769 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective, national, multi-centre study will include patients with stage III triple-negative breast cancer (TNBC) who are planned to start with standard (neo)adjuvant systemic treatment. The study will gather clinico-pathological, treatment and follow-up information of participating patients through Dutch databases. Participating patients will be asked to complete cancer specific and more generic quality of life questionnaires at nine time points during and after their anticancer treatment in a mobile application. For all patients who have consented to additional blood collection, to assess the course of dynamic ctDNA during (neo)adjuvant chemotherapy and its relation with outcome, two tubes will be collected at four different time points.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged 18 years or older * Histologically confirmed adenocarcinoma of the breast * Assumed clinical or pathological stage III (TNM) breast cancer * Breast tumor must be: * HER2-negative: i.e. either score 0 or 1 at immunohistochemistry or score 2 at immunohistochemistry and negative at in situ hybridization (ISH, CISH or FISH) * Hormone receptor negative i.e. an estrogen receptor (ER) of \<10% and progesterone receptor (PR) of \<10%.; or in case of a histological grade III tumor an ER of \<50% and a PR of \<50%. * Patients are planned to receive the complete standard of care in the Netherlands; neo-adjuvant chemotherapy according to local practise * Participating patients have to be able to use a mobile phone, tablet, laptop and/or computer and understand the Dutch language Exclusion Criteria: * Evidence of distant metastases. Staging examinations should have been performed according to Dutch national guidelines. * Patients who are only treated systemically in the adjuvant setting * Participation in another clinical study with an treatment intervention during the course of this study.
💊

What it tests

  • Not listed
📍

Where

9 sites
Medical spectrum Twente
Enschede, Netherlands
Amsterdam University Medical Center
Amsterdam, Netherlands
The Netherlands Cancer Institute
Amsterdam, Netherlands
Amphia
Breda, Netherlands
Deventer ziekenhuis
Deventer, Netherlands
UMCG
Groningen, Netherlands
Maastricht University Medical Center
Maastricht, Netherlands
CWZ
Nijmegen, Netherlands

…and 1 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy